Perpetual Ltd Acquires 1,571 Shares of Johnson & Johnson (NYSE:JNJ)

Perpetual Ltd grew its holdings in shares of Johnson & Johnson (NYSE:JNJFree Report) by 6.8% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 24,712 shares of the company’s stock after buying an additional 1,571 shares during the period. Perpetual Ltd’s holdings in Johnson & Johnson were worth $3,909,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of JNJ. Pathway Financial Advisors LLC raised its position in Johnson & Johnson by 4.3% in the 4th quarter. Pathway Financial Advisors LLC now owns 5,438 shares of the company’s stock valued at $852,000 after buying an additional 226 shares during the last quarter. Daiwa Securities Group Inc. raised its position in Johnson & Johnson by 5.5% in the 4th quarter. Daiwa Securities Group Inc. now owns 297,850 shares of the company’s stock valued at $46,685,000 after buying an additional 15,490 shares during the last quarter. OneAscent Financial Services LLC raised its position in Johnson & Johnson by 82.8% in the 4th quarter. OneAscent Financial Services LLC now owns 9,838 shares of the company’s stock valued at $1,542,000 after buying an additional 4,457 shares during the last quarter. Vestmark Advisory Solutions Inc. raised its position in Johnson & Johnson by 12.7% in the 4th quarter. Vestmark Advisory Solutions Inc. now owns 19,587 shares of the company’s stock valued at $3,070,000 after buying an additional 2,201 shares during the last quarter. Finally, TrueMark Investments LLC purchased a new stake in Johnson & Johnson in the 4th quarter valued at $1,458,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

Johnson & Johnson stock traded up $2.12 during midday trading on Thursday, reaching $147.77. The stock had a trading volume of 8,749,383 shares, compared to its average volume of 7,371,235. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $355.63 billion, a PE ratio of 9.21, a P/E/G ratio of 2.42 and a beta of 0.53. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The firm’s 50-day moving average price is $148.04 and its 200 day moving average price is $154.49.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.68 EPS. As a group, research analysts predict that Johnson & Johnson will post 10.63 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were issued a dividend of $1.24 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date was Monday, May 20th. This represents a $4.96 annualized dividend and a dividend yield of 3.36%. Johnson & Johnson’s payout ratio is presently 30.92%.

Analysts Set New Price Targets

A number of equities research analysts recently commented on JNJ shares. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a research report on Monday. The Goldman Sachs Group started coverage on Johnson & Johnson in a research report on Thursday, May 30th. They set a “neutral” rating and a $160.00 target price for the company. StockNews.com lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Monday, June 10th. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and raised their target price for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Thursday. Eight equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has an average rating of “Hold” and an average target price of $174.07.

View Our Latest Research Report on Johnson & Johnson

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.